Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies-Reference-Cited by-同舟云学术

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

Published:2017-08-18 Issue:3 Volume:179 Page:430-438
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rule Simon¹^ORCID,Dreyling Martin²,Goy Andre³,Hess Georg⁴,Auer Rebecca⁵,Kahl Brad⁶,Cavazos Nora⁷,Liu Black⁸,Yang Shiyi⁹,Clow Fong⁷,Goldberg Jenna D.⁹,Beaupre Darrin⁷,Vermeulen Jessica¹⁰,Wildgust Mark⁹,Wang Michael¹¹

Affiliation:

1. Plymouth University Medical School; Plymouth UK

2. Klinikum der Universität München; Munich Germany

3. John Theurer Cancer Center at Hackensack University Medical Center; Hackensack NJ USA

4. University Medical School of the Johannes Gutenberg University; Mainz Germany

5. St. Bartholomew's Hospital; Barts Health NHS Trust; London UK

6. Washington University School of Medicine; St. Louis MO USA

7. Pharmacyclics; Sunnyvale CA USA

8. Janssen China Research & Development; Shanghai China

9. Janssen Research & Development; Raritan NJ USA

10. Janssen Research & Development; Leiden The Netherlands

11. The University of Texas MD Anderson Cancer Center; Houston TX USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14870/fullpdf

Reference32 articles.

1. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse;Bernard;Blood,2015

2. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience;Bhatt;Leukemia & Lymphoma,2016

3. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma;Brown;American Society of Hematology,2014

4. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy;Buggy;International Reviews of Immunology,2012

5. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;New England Journal of Medicine,2015

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study;Hematology Reports;2024-01-18

2. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance;International Journal of Hematology;2024-01-09

3. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

4. Clinical features and prognostic analysis of the blastoid variant of mantle cell lymphoma: An analysis of 20 patients from two centers;Cancer Pathogenesis and Therapy;2024-01

5. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma;Leukemia Research;2023-11